SubHero Banner

FluLaval® Quadrivalent (influenza vaccine) – Expanded indication

November 18, 2016 – GlaxoSmithKline announced the FDA approval of FluLaval Quadrivalent (influenza vaccine) for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluLaval Quadrivalent is approved for use in persons ≥ 6 months of age.

Download PDF